Highlights,Rhumbline Advisers increased its position in Glaukos Corporation, reflecting sustained institutional interest.,Key ...

Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The ...

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx ...

Truist Financial analyst Richard Newitter maintained a Buy rating on Glaukos (GKOS – Research Report) today. The company’s shares closed ...

State of New Jersey Common Pension Fund D grew its position in Glaukos Co. (NYSE:GKOS – Free Report) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,883 shares of the ...

Rhumbline Advisers lifted its holdings in Glaukos Co. (NYSE:GKOS – Free Report) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The ...

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

Glaukos Corp (GKOS) reports robust sales growth and outlines strategic initiatives for 2025, while navigating currency and reimbursement challenges.

The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. The glaucoma treatments developer ...